人民财讯12月24日电，深交所公告，深港通下的港股通标的证券名单调整，调入百奥赛图-B(02315)， 12月24日起生效。 ...

证券时报·数据宝统计显示，截至12月23日，已经有24家公司公布了2025年度业绩预告。业绩预告类型 显示，预增公司18家，报喜公司比例为75.00%；业绩预降、预亏公司分别有2家、1家。 业绩预喜公司中，以预计净利润增幅中值统计，共有1家公司净利润增幅超100%；净利润增幅在 50%~100%之间的有1家。具体到个股看，百奥赛图预计净利润增幅最高。公司预计全年实现净利润增 幅中值为303.57%；C沐曦、N锡华预计全年净利润同比增幅中值分别为54.22%、48.25%，增幅位列第 二、第三。 证券时报·数据宝统计显示，业绩预计翻倍股今年以来平均下跌21.52%，表现弱于沪指。（数据宝） 24家公司公布了全年业绩预告，业绩预增公司有18家，占比75.00%。 | 代码 | 简称 | 业绩预告日 | 预计净利润增幅中值 | 最新收盘价 | 今年以来涨跌幅 | 行业 | | --- | --- | --- | --- | --- | --- | --- | | | | 期 | （%） | （元） | （%） | | | 688796 | 百奥赛 图 | 2025.12.09 | 303.57 | 51.64 | ...

资料显示，百奥赛图(北京)医药科技股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业 基地宝参南街12号院，成立日期2009年11月13日，上市日期2025年12月10日，公司主营业务涉及百奥赛 图（北京）医药科技股份有限公司是一家主要提供抗体药物研发和临床前研究服务的中国公司。该公司 运营五个分部。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分 部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动 物，亦向客户授出若干模式动物的许可。抗体开发分部识别有潜力成为候选药物的抗体，并就潜在治疗 性抗体分子对外授权或与合作伙伴合作。创新药开发分部研发创新药，专注肿瘤学和自身免疫性疾病治 疗。 责任编辑：小浪快报 12月22日，百奥赛图涨3.14%，成交额3.04亿元。两融数据显示，当日百奥赛图获融资买入额3587.06万 元，融资偿还2158.95万元，融资净买入1428.11万元。截至12月22日，百奥赛图融资融券余额合计1.09 亿元。 融资方面，百奥赛图当日融资买入3587.06万元。当前融资余额1.09亿元，占流通市值的5.88%。 ...

Core Viewpoint - The "Annual A+H Excellence Company Award" recognizes outstanding listed companies operating on both A-share and H-share platforms, highlighting their business growth, financial stability, and governance [1] Group 1: Award Winners - The following companies received the "Annual A+H Excellence Company Award": BaiO Saite (688796.SH/02315.HK), Dazhong Public Utilities (600635.SH/01635.HK), CATL (300750.SZ/03750.HK), Seres (601127.SH/09927.HK), and CIMC (000039.SZ/02039.HK) [1] - The award aims to honor companies that set benchmarks in business growth, financial health, and corporate governance while demonstrating exceptional capabilities in value integration and strategic leadership [1] Group 2: Event Overview - The event titled "Technology Empowerment, Capital Breakthrough" was held online by Gelonghui on December 22, where the award winners were announced [1] - Gelonghui's mission is to create a reference value ranking of listed companies and unicorns in the investment community, covering all listed companies on major exchanges including the Hong Kong Stock Exchange, Shanghai Stock Exchange, Shenzhen Stock Exchange, New York Stock Exchange, and NASDAQ [2]

Group 1 - The core viewpoint of the news is that BaiO Technology's stock has experienced a decline of 22.28% this year and an 8.61% drop in the last five trading days, with current trading activity showing a slight increase in stock price [1] - BaiO Technology is a Chinese company primarily engaged in antibody drug research and preclinical research services, established on November 13, 2009, and listed on December 10, 2025 [2] - The company operates five divisions, including gene editing services, preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and innovative drug development focused on oncology and autoimmune diseases [2] Group 2 - BaiO Technology is categorized under the pharmaceutical and biological industry, specifically in medical services and medical research outsourcing [2] - The company is associated with several concept sectors, including cell therapy, innovative drugs, pre-profit and profit growth, newly listed stocks, and specialized and innovative enterprises [2]

Group 1 - The core viewpoint of the news is that BaiO Technology's stock has experienced a significant decline this year, with a drop of 21.72% and a recent 5-day decline of 11.54% [1] - As of December 19, BaiO Technology's stock price was 51.51 CNY per share, with a market capitalization of 23.02 billion CNY [1] - The company experienced a net outflow of main funds amounting to 6.38 million CNY, with large orders showing a buy of 22.73 million CNY and a sell of 28.98 million CNY [1] Group 2 - BaiO Technology, established on November 13, 2009, is located in the Daxing District of Beijing and specializes in antibody drug research and preclinical research services [2] - The company operates five divisions, including gene editing services, preclinical pharmacology and efficacy evaluation, model animal sales, antibody development, and innovative drug development focusing on oncology and autoimmune diseases [2] - BaiO Technology is categorized under the pharmaceutical and biological industry, specifically in medical services and medical research outsourcing, with concepts including innovative drugs, cell therapy, and CRO [2]

Group 1 - A total of 20 companies have announced their performance forecasts for the year 2025, with 14 expecting profit increases, 2 expecting profit decreases, and 1 forecasting a loss [1][2] - The companies with the highest expected profit increase include Baiao with a projected increase of 303.57% and Lixun Precision with an expected increase of 26.09% [1] - Companies such as C. Angrui and Jinhua are forecasting profit decreases of -19.44% and -5.47%, respectively [2] Group 2 - The electronic industry has several companies forecasting profit increases, including C. Muxi with a 54.22% reduction in losses and Moer Thread with a 41.36% reduction in losses [1] - The machinery and equipment sector shows positive forecasts, with companies like Aomei and Nante expecting profit increases of 16.44% and 13.02%, respectively [1] - The power equipment industry has companies like Hongyuan and Xintong Electronics forecasting profit increases of 21.42% and 5.40%, respectively [1]

融券方面，百奥赛图12月18日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元。 12月18日，百奥赛图涨0.40%，成交额3.15亿元。两融数据显示，当日百奥赛图获融资买入额2735.36万 元，融资偿还2398.44万元，融资净买入336.92万元。截至12月18日，百奥赛图融资融券余额合计 9173.00万元。 融资方面，百奥赛图当日融资买入2735.36万元。当前融资余额9173.00万元，占流通市值的5.07%。 资料显示，百奥赛图(北京)医药科技股份有限公司位于北京市大兴区中关村科技园区大兴生物医药产业 基地宝参南街12号院，成立日期2009年11月13日，上市日期2025年12月10日，公司主营业务涉及百奥赛 图（北京）医药科技股份有限公司是一家主要提供抗体药物研发和临床前研究服务的中国公司。该公司 运营五个分部。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分 部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动 物，亦向客户授出若干模式动物的许可。抗体开发分 ...

Core Insights - A total of 19 companies have announced their performance forecasts for the year 2025, with 13 expecting profit increases, 2 forecasting profit declines, and 1 predicting a loss [1] Performance Forecast Summary - **Profit Increase**: - Companies such as Bai'ao (688796) expect a profit increase of 303.57%, with a closing price of 50.25 and a year-to-date decline of 23.63% [1] - Lixun Precision (002475) anticipates a profit increase of 26.09%, with a closing price of 58.66 and a year-to-date increase of 44.73% [1] - Other notable companies with profit increases include Hongyuan (920018) at 21.42%, Aomei (920080) at 16.44%, and China Uranium (001280) at 11.42% [1] - **Profit Decline**: - Zhongcheng (920003) forecasts a profit decline of 4.14%, with a closing price of 34.15 and a year-to-date decline of 11.39% [1] - Jinhua (920015) expects a profit decline of 5.47%, with a closing price of 51.11 and a year-to-date increase of 20.86% [1] - **Loss Forecast**: - C Muxi (688802) is predicting a loss but expects to reduce losses by 54.22%, with a closing price of 829.90 [1]

Group 1 - A total of 18 companies have announced their performance forecasts for the year 2025, with 12 expecting profit increases, 2 expecting profit decreases, and 1 forecasting a loss [1] - The companies with the highest expected profit increase include Baiao with a forecasted increase of 303.57% and Lixun Precision with a forecasted increase of 26.09% [1] - Companies such as Cangrui are predicting a loss of 19.44%, while Zhongcheng and Jinhua expect profit decreases of 4.14% and 5.47% respectively [1] Group 2 - The industries represented in the forecasts include pharmaceuticals, electronics, power equipment, machinery, and automotive sectors [1] - Notable companies in the electronics sector include Nuxi and Moer Thread, both of which are expecting reduced losses [1] - The automotive industry has companies like Hai'an Group with a stable forecast and TaiKai Ying with a profit increase of 10.44% [1]